A 4-week Randomized, Double-blind, Crossover Study to Assess the Effect of a New LABA/LAMA Combination Versus LAMA Alone on Exertional Dyspnea, Exercise Endurance and Neuromechanical Coupling in Patients With GOLD Stage II COPD

Trial Profile

A 4-week Randomized, Double-blind, Crossover Study to Assess the Effect of a New LABA/LAMA Combination Versus LAMA Alone on Exertional Dyspnea, Exercise Endurance and Neuromechanical Coupling in Patients With GOLD Stage II COPD

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Umeclidinium/vilanterol (Primary) ; Umeclidinium
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Nov 2014 Status changed from recruiting to completed as per ClinicalTrials.gov.
    • 14 Apr 2014 Planned End Date changed from 1 Jun 2014 to 1 Dec 2014, as per ClinicalTrials.gov record.
    • 25 Sep 2013 Planned End Date changed from 1 Dec 2013 to 1 Jun 2014, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top